Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by impairments in memory and cognitive abilities. The development of new immunotherapies targeting beta-amyloid (Aβ) and tau protein deposition in the brain is ushering in great advances in clinical management. Here, MAPT is linked to Alzheimer disease.